AstraZeneca Results Presentation Deck

BioPharmaceuticals: Respiratory & Immunology Total Revenue ($m) 800 700 600 500 400 300 200 100 ☐EM 0 EROW ■ Europe US Q2 141 99 176 264 Symbicort 4% growth at CER to $1,288m in H1 2023 Q3 2021 151 96 155 274 Q4 152 96 171 262 Q1 167 91 157 259 Q2 139 98 155 222 2022 Q3 169 91 133 237 Q4 133 95 137 255 43 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Q1 229 79 147 233 2023 Q2 177 86 137 200 Total Revenue ($m) 300 250 200 150 100 50 0 ☐EM ☐EROW Europe US Q2 119 12 18 18 Pulmicort 11% growth at CER to $346m in H1 2023 Q3 2021 173 12 15 17 Q4 193 13 23 19 Q1 164 13 18 22 APPENDIX | H1 2023 Product Performance Q2 72 12 17 15 2022 Q3 103 12 14 16 Q4 123 12 19 12 Q1 182 9 20 10 2023 Q2 90 11 16 7

View entire presentation